Matthew Orton
Overview
Explore the profile of Matthew Orton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hindocha S, Hunter B, Linton-Reid K, George Charlton T, Chen M, Logan A, et al.
Radiother Oncol
. 2024 Apr;
195:110266.
PMID: 38582181
Background: Pneumonitis is a well-described, potentially disabling, or fatal adverse effect associated with both immune checkpoint inhibitors (ICI) and thoracic radiotherapy. Accurate differentiation between checkpoint inhibitor pneumonitis (CIP) radiation pneumonitis...
2.
Paller C, Barata P, Lorentz J, Appleman L, Armstrong A, DeMarco T, et al.
Prostate
. 2023 Nov;
84(3):292-302.
PMID: 37964482
Background: Recently approved treatments and updates to genetic testing recommendations for prostate cancer have created a need for correlated analyses of patient outcomes data via germline genetic mutation status. Genetic...
3.
Doyle J, Patel P, Petrou N, Shur J, Orton M, Kumar S, et al.
Langenbecks Arch Surg
. 2023 Jun;
408(1):226.
PMID: 37278924
Introduction: Cross-sectional imaging plays an integral role in the management of upper gastrointestinal (UGI) cancer, from initial diagnosis and staging to determining appropriate treatment strategies. Subjective imaging interpretation has known...
4.
Hindocha S, Charlton T, Linton-Reid K, Hunter B, Chan C, Ahmed M, et al.
NPJ Precis Oncol
. 2022 Nov;
6(1):87.
PMID: 36418522
No abstract available.
5.
Tran P, Lowe K, Tsai H, Song D, Hung A, Hearn J, et al.
J Clin Oncol
. 2022 Nov;
41(6):1307-1317.
PMID: 36367998
Purpose: We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men...
6.
Hindocha S, Charlton T, Linton-Reid K, Hunter B, Chan C, Ahmed M, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):77.
PMID: 36302938
Recurrence occurs in up to 36% of patients treated with curative-intent radiotherapy for NSCLC. Identifying patients at higher risk of recurrence for more intensive surveillance may facilitate the earlier introduction...
7.
Hindocha S, Charlton T, Linton-Reid K, Hunter B, Chan C, Ahmed M, et al.
EBioMedicine
. 2022 Mar;
77:103911.
PMID: 35248997
Background: Surveillance is universally recommended for non-small cell lung cancer (NSCLC) patients treated with curative-intent radiotherapy. High-quality evidence to inform optimal surveillance strategies is lacking. Machine learning demonstrates promise in...
8.
Kousi E, Messiou C, Miah A, Orton M, Haas R, Thway K, et al.
Br J Radiol
. 2021 Sep;
94(1126):20210310.
PMID: 34545764
Objectives: Myxoid liposarcomas (MLS) show enhanced response to radiotherapy due to their distinctive vascular pattern and therefore could be effectively treated with lower radiation doses. This is a descriptive study...
9.
Doran S, Kumar S, Orton M, dArcy J, Kwaks F, OFlynn E, et al.
Cancer Imaging
. 2021 May;
21(1):37.
PMID: 34016188
Background: Most MRI radiomics studies to date, even multi-centre ones, have used "pure" datasets deliberately accrued from single-vendor, single-field-strength scanners. This does not reflect aspirations for the ultimate generalisability of...
10.
Barwick T, Orton M, Koh D, Kaiser M, Rockall A, Tunariu N, et al.
Br J Radiol
. 2021 Mar;
94(1120):20200682.
PMID: 33733812
Objective: To assess intra- and inter-reader variability of apparent diffusion coefficient (ADC) and fat fraction (FF) measurement in focal myeloma bone lesions and the influence of lesion size. Methods: 22...